Jongmyung Kim, MD, PhD

Excellent thoracic tumor board discussion at APPOS with outstanding colleagues. Always a pleasure to collaborate. @ASCO

Next up is a randomised phase 3 study of concurrent chemoRT in LS-SCLC ➡️ 530 pts randomised to 45Gy/5# vs 60Gy/30# 🚨No difference in survival outcomes 📢 Reduced pneumonitis and lymphoma rates New SOC? #WCLC25

Congratulations! @MoffittRadOnc @MoffittNews @MoffittResearch @ASTRO_org

New in #practicalRO: A Case-Based Guide: Demonstrating the ReCOG Consensus for Dosimetric Assessment and Reporting in Reirradiation. #radonc tinyurl.com/proczhang

In clinical trials, higher Keytruda (pembrolizumab) doses didn’t improve outcomes. New real-world data suggests it could be more complex. Drug levels after just one cycle were significantly linked to survival in metastatic #LungCancer - 10 months median overall survival in those with lower levels vs 34 months in those with higher levels. Lower levels also meant less complete blocking of the PD-1 receptor (the mechanism the drug relies on). A routine blood test after cycle 1 could identify people less likely to benefit early enough to act. doi.org/10.1016/j.phrs… #LCSM

Neurocognition after brain irradiation: dose-volume effects and regional radiosensitivity − a systematic review by the ESTRO CNS focus group - ScienceDirect sciencedirect.com/science/articl…

Congrats to @KOSJ12 and Team @JMBryantMD @Naghavi_MD @naqvi_mahrukh @JulioPowSangMD @UrogerliMD @jtorresroca @gdgrass @rohitjainMD on their novel Ph2 study of EBRT/HDR, hormone therapy, and nivolumab in grade group 5 PCa @OncoAlert @MoffittRadOnc @MoffittNews

The Moffitt team had a fantastic time at ARS 2026! Congratulations to @aiims2738 on the Travel Grant Award!

Online here: nature.com/articles/s4158… Open access here: rdcu.be/ff6YJ Key supporters of this work are @CR_UK , @CRUKLungCentre , @UCLHresearch alongside many others

📌 Cardiac Dose and Survival Outcomes Following SBRT for Primary and Metastatic Lung Tumors: A Substructure-Based Analysis 🔗 advancesradonc.org/article/S2452-… @ASTRO_org @ChariteBerlin 👉🏻 Dose–response relationships are driven by cardiac substructures rather than by whole-heart exposure. 👉🏻Elevated EQD₂ doses to upper cardiac structures, such as the left atrium and superior vena cava, were independently associated with reduced overall survival. 👉🏻 There was a trend toward decreased survival with higher doses to the cardiac base, indicating a consistent vulnerability of this region.

Despite screening recommendations, only 16% of people who are eligible undergo #LungCancer screening. Moffitt’s mobile lung screening unit is working to reshape that narrative! 🫁 Learn more about upcoming events and screenings: moffitt.org/endeavor/archi…

Reirradiation (#reRT) offers renewed hope for cancer recurrence—but comes with serious risks. Precision techniques, advanced imaging, and multidisciplinary care are essential. Don't miss this definitive review on this evolving treatment️: 🔗 acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @OncoAlert

Happening Now: Day two of the 8th International Workshop on CAR-T and Bispecifics. Talking with Chair @DrFredLocke of @MoffittNews. We’d love to invite participants of #iWCART26 to join us back in Tampa Oct. 9-11 for the Cell Coast Conference — visit Moffitt.org/CellCoast to register! @VJHemOnc @VJOncology

Any good review articles/resources discussing post-SBRT changes in lung to share with my local referring team of physicians? 🤔 I personally like the ESTRO 2025 guidelines 📝🫁 thegreenjournal.com/article/S0167-…

🚨 New international consensus from the International Benign Target Volume Group just out! Standardizing 3D target volume definition for osteoarthritis in radiotherapy: bringing anatomical precision to LDRT #RadOnc #LDRT #Osteoarthritis #IBTVG redjournal.org/article/S0360-…

Announcing RadOncSmartLearn 2.0, Free AI-powered platform for mock oral exams Socratic tutor sessions backed by the latest guidelines. Complete Speech System, case exhibits, structured follow-up, and mastery tracking and more...

#ASTRO23 #JACCCardioOnc SimPub: #MACE occurs in >20% of those undergoing RT in a median time of <2 yrs. In this article, @DoctorNoMD, et al exhibit the use of coronary artery dosimetry & imaging biomarkers to help predict MACE risk & inform personalized RT bit.ly/3rvQvzA

Great discussion on KRAS G12C at #AACR26 from @DocSacher. Early generation KRAS(off) inhibitors approved and active, but novel agents demonstrating some efficacy and safety advantages. Will this yield to combinations or to emerging KRAS(on) strategies?

🩻🦴SBRT vs conv EBRT → fracture risk? This comes up a lot at QA rounds. A recent review @JAMANetworkOpen was helpful: based on available RCTs, there appears to be no diff in fracture rates. SC.29 (led by @SahgalArjun @CDNCancerTrials) may add further insight.

New in the #RedJournal from @JablonskaPaola et al: A novel multimodal model to predict radiation necrosis risk in brain metastases treated with SRS/FSRT. The Necrosis Prediction Index (NPI) integrates baseline blood biomarkers (CXCL11, MUC-16) with PTV. tinyurl.com/rjjablonska

@SA_Rosenberg @BHaffty @SalmaJabbour1 @MoffittRadOnc Congratulations, Steve. Absolutely one of the best training programs with great mentors! @RU_RadOnc

This was my absolute pleasure to visit ! Thanks so much for having me! It is an amazing group of residents and faculty !! I got my start in rad onc at RWJMS as a medical student and owe so much of my success to my mentors there !!! @BHaffty @SalmaJabbour1 @MoffittRadOnc